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Summary
Background—Patients with squamous non-small-cell lung cancer that is refractory to multiple 
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 
immune checkpoint inhibitor antibody, for patients with advanced, refractory, squamous non-
small-cell lung cancer.
Methods—We did this phase 2, single-arm trial at 27 sites (academic, hospital, and private 
cancer centres) in France, Germany, Italy, and USA. Patients who had received two or more 
previous treatments received intravenous nivolumab (3 mg/kg) every 2 weeks until progression or 
unacceptable toxic effects. The primary endpoint was the proportion of patients with a confirmed 
objective response as assessed by an independent radiology review committee. We included all 
treated patients in the analyses. This study is registered with ClinicalTrials.gov, number 
NCT01721759.
Findings—Between Nov 16, 2012, and July 22, 2013, we enrolled and treated 117 patients. 17 
(14·5%, 95% CI 8·7–22·2) of 117 patients had an objective response as assessed by an independent 
radiology review committee. Median time to response was 3·3 months (IQR 2·2–4·8), and median 
duration of response was not reached (95% CI 8·31–not applicable); 13 (77%) of 17 of responses 
were ongoing at the time of analysis. 30 (26%) of 117 patients had stable disease (median duration 
6·0 months, 95% CI 4·7–10·9). 20 (17%) of 117 patients reported grade 3–4 treatment-related 
adverse events, including: fatigue (five [4%] of 117 patients), pneumonitis (four [3%]), and 
diarrhoea (three [3%]). There were two treatment-associated deaths caused by pneumonia and 
ischaemic stroke that occurred in patients with multiple comorbidities in the setting of progressive 
disease.
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Interpretation—Nivolumab has clinically meaningful activity and a manageable safety profile in 
previously treated patients with advanced, refractory, squamous non-small cell lung cancer. These 




During immunosurveillance, the immune system is capable of recognising and destroying 
tumour cells; however, tumours can escape elimination by the immune system through 
activation of inhibitory feedback loops or (so-called immunological brakes) that are essential 
to avoid autoimmune events, and so can create barriers to T-cell activation and tumour 
rejection.1,2 The PD-1 pathway is one such inhibitory pathway, and its activation is exploited 
by several cancer types, including lung cancer. Inhibition of the PD-1 pathway is a novel 
therapeutic approach for treating cancer.3 Nivolumab, a fully human, IgG4 immune 
checkpoint inhibitor antibody, binds PD-1 on activated immune cells to disrupt PD-1 
interaction with PD-L1 and PD-L2 ligands, thereby attenuating inhibitory signals and 
augmenting the host antitumour response.3 Nivolumab has anti-cancer activity against 
several tumour types, including non-small-cell lung cancer.4–7 In a phase 1 study5–7 of about 
300 patients with advanced solid tumors, nivolumab treatment resulted in 22 (17%) of 129 
patients with non-small-cell lung cancer achieving an objective response. Treatment with 
nivolumab also resulted in overall survival of 42% (95% CI 33–50) at 1 year, 24% (17–33) 
at 2 years, and 18% (11–25) at 3 years; similar results have been reported for non-squamous 
and squamous histological subtypes.5–7
Lung cancer is a major health burden, with more than 1·6 million new cases diagnosed per 
year and 1·3 million deaths per year.8 Most cases (85%) are non-small-cell lung cancer, 
consisting of non-squamous (70%) and squamous (30%) histological subtypes, and half of 
patients present with incurable metastatic disease.9–11 Prognosis for refractory squamous 
non-small-cell lung cancer is very poor, with median overall survival of between 4·0–6·5 
months, 1-year survival of 6–18%, and 2-year survival of 3%.12–14
Recent advances in treatment for non-small-cell lung cancer have been restricted to patients 
with non-squamous disease, with little progress for the squamous subtype. This might be 
partly caused by the mutational complexity of squamous non-small-cell lung cancer, which 
limits the activity of the newly developed targeted therapies, and leaves systemic 
chemotherapy as the mainstay of treatment. Because of the absence of approved or 
efficacious treatments for patients with refractory squamous non-small-cell lung cancer, best 
supportive care or clinical trials remain the primary approaches for this population. 
Accordingly, we did CheckMate 063 to assess the therapeutic activity of nivolumab for 
patients with advanced, refractory squamous non-small-cell lung cancer.
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Study design and participants
This study was an international, phase 2, single-arm trial at 27 sites (academic, hospital, and 
private cancer centres) in four countries: seven in France, three in Germany, three in Italy, 
and 14 in USA (one site in the USA enrolled patients but never treated them).
We included patients with histologically or cytologically documented stage IIIB or IV 
squamous non-small-cell lung cancer, and disease measurable by CT or MRI. Patients had to 
be aged 18 years or older, have an Eastern Cooperative Oncology Group performance status 
of 0 or 1, and have acceptable haematological, renal, and hepatic function (appendix). The 
following laboratory tests were done to assess patient eligibility: complete blood count with 
differential, serum chemistry tests, aspartate aminotransferase, alanine aminotransferase, 
total bilirubin, alkaline phosphatase, albumin, lactose dehydrogenase, thyroid stimulating 
hormone, free T3, free T4, hepatitis B surface antigen, and hepatitis C antibody or hepatitis 
C RNA.
Patients had to have had disease progression or recurrence after both a platinum doublet-
based chemotherapy regimen and at least one additional systemic treatment (appendix). 
Patients with treated stable brain metastases who had neurologically returned to baseline for 
at least 2 weeks before enrolment were eligible. Exclusion criteria (appendix) included 
autoimmune disease, disorders requiring systemic immunosuppressive drugs, previous 
treatment with an antibody or drug specifically targeting T-cell co-stimulation or checkpoint 
pathways, positive test for HIV, hepatitis B, hepatitis C, or symptomatic interstitial lung 
disease (patients with a history of pneumonitis were not excluded). Previous cancer 
treatment, radiotherapy, or radiosurgery must have been completed at least 2 weeks before 
receiving the first dose of study drug. Patient selection was not based on estimated survival; 
typical median survival in this population is 4·0–6·5 months.12–14
The study protocol was approved by institutional review boards and independent ethics 
committees of each institute, and the study was done in accordance with international 
standards of good clinical practice. All patients or their legal representatives provided 
written informed consent before enrolment.
Procedures
Nivolumab (Bristol-Myers Squibb, Princeton, NJ, USA) was supplied as a solution for 
injection (100 mg; 10 mg/mL). Patients received nivolumab 3 mg/kg as an intravenous 
infusion every 2 weeks (1 cycle) until disease progression or unacceptable toxic effects. 
Treatment after progression was permitted if a patient had investigator-assessed clinical 
benefit (continuing disease or symptom control despite radiographic progression), stable 
performance status, and was tolerating nivolumab. This decision was taken based on 
evidence7,15 that some patients treated with immunotherapy might derive clinical benefit 
(response or prolonged disease stabilisation) despite initial evidence of progressive disease. 
The decision to continue treatment was at the discretion of the treating physician.
Rizvi et al. Page 4













We based the dose and schedule of nivolumab on safety and activity data from a phase 1 
study,6 which showed a similar proportion of objective responses in patients treated with 3 
mg/kg and those treated with 10 mg/kg; both of these doses achieved better responses than 
with a 1 mg/kg dose. The safety profile was much the same for each dose and for different 
tumour types in the phase 1 trial.
Dose modifications of nivolumab were not permitted. Delays of nivolumab dose were 
allowed for protocol-defined reasons, including the occurrence of: grade 2 or worse non-skin 
treatment-related adverse events; grade 3 skin treatment-related adverse events; and grade 3 
treatment-related laboratory abnormalities, with protocol-defined exceptions for 
lymphopenia, leucopenia, aspartate aminotransferase, alanine aminotransferase, or total 
bilirubin (appendix). Reasons for discontinuation from nivolumab treatment included the 
occurrence of grade 2 treatment-related uveitis or ocular toxic effects not responsive to 
treatment; grade 3 non-skin treatment-related adverse events or thrombocytopenia lasting 
more than 7 days, or grade 3 uveitis, pneumonitis, or hypersensitivity reaction of any 
duration; high-grade (eg, >5–10 times the upper limit of normal) liver function test 
abnormalities or concurrent increases of aspartate aminotransferase, alanine 
aminotransferase, or bilirubin; any grade 4 treatment-related adverse events or laboratory 
abnormalities, with exceptions for lymphopenia, leucopenia, or neutropenia for less than 7 
days. Clinical and laboratory safety assessments were done for all treated patients. Adverse 
events were assessed at screening, every 2 weeks during treatment, and up to 100 days after 
receiving the last nivolumab dose. Severity of adverse events was graded on the basis of the 
National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0).16 
Immune-mediated events were defined as adverse events with potential immunological basis 
requiring frequent monitoring and potential intervention with immune suppression or 
endocrine treatment. Adverse events were managed with established safety guidelines.
Radiographic tumour assessments were done at screening, 8 weeks after the start of 
treatment, and every 6 weeks thereafter until disease progression or until discontinuation of 
nivolumab for patients treated beyond progression. Survival was assessed every 3 months 
after completion of treatment, until death or withdrawal of consent.
We measured PD-L1 protein expression in pre-treatment, formalin-fixed, paraffin-embedded 
tumour specimens with a validated, automated immunohistochemical assay (Dako, 
Carpinteria, CA, USA), with samples categorised as positive when tumour cell membranes 
were stained to any intensity in 1%, 5%, and 10% of cells in a section with a minimum of 
100 assessable tumour cells. We used a cutoff of 5% to define PD-L1 positivity, on the basis 
of preliminary findings from a phase 1 study,6,7 and because the difference in responses 
between PD-L1 positive and PD-L1 negative patients was not greater when using a 1% 
cutoff than when using a 5% cutoff (appendix), prospectively defined in the statistical 
analysis plan. In cases for which the tissue sample was not optimally collected or prepared 
(ie, improperly fixed, contained sectioning artifacts such as folding, or were found not to 
contain tumour tissue) or for which PD-L1 expression could not be assessed, PD-L1 status 
was categorised as unevaluable.
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The primary endpoint was the proportion of patients with a confirmed objective response (ie, 
the percentage of all treated patients with a best overall response of confirmed complete or 
partial response), as assessed by an independent radiology review committee (IRC) using 
Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1).17 Best overall 
response was defined as the best response designation recorded between the date of first 
dose and the date of initial objectively documented tumour progression per RECIST v1.1, or 
the date of subsequent therapy, whichever occurred first. Objective response was further 
characterised by the duration of response, defined as the time from first confirmed response 
to the date of initial radiographic progression for patients with complete response or partial 
response.
The secondary endpoint was the proportion of patients with investigator-assessed confirmed 
objective response using RECIST 1.1. Exploratory endpoints were to characterise 
pharmacokinetics of nivolumab and explore exposure-response (exposure safety and 
exposure efficacy) relationships with respect to selected safety and efficacy endpoints and to 
characterise immunogenicity of nivolumab, safety and tolerability of nivolumab, 
progression-free survival and overall survival of all treated patients, and association between 
the proportion of patients with an objective response rate and PD-L1 expression in all 
patients. Progression-free survival was defined as the time from the first dose of nivolumab 
to the date of first documented tumour progression or death from any cause. Overall survival 
was defined as the time from the date of first dose to the date of death from any cause or last 
known date alive for patients who were alive at the time of data analysis. Patients who died 
without a reported previous progression were considered to have progressed on the date of 
their death. Patients who neither progressed nor died were censored on the date of their last 
tumour assessment. Patients who received subsequent cancer treatment without a reported 
progression were censored at the date of the last tumour assessment before starting further 
treatment. Patients who did not have any on-study tumour assessments and did not die were 
censored on the date of the first dose of nivolumab. Patients who were not evaluable for best 
best overall response by the independent radiology review committee were recorded as 
having indeterminate best overall response. Patients without on-study scans were recorded 
as having best overall response not reported. These assessments were preplanned.
Statistical analysis
We designed the study to treat roughly 100 patients, such that the maximum width of the 
exact two-sided 95% CI was 20% when 10–50% of participants had an objective response. 
We did the safety and activity analyses in all treated patients, defined as those who received 
at least one dose of nivolumab. An initial data lock including investigator-assessed endpoints 
occurred on March 6, 2014. Data for endpoints assessed by the independent radiology 
review committee, overall survival, safety, and PD-L1 expression were updated on July 23, 
2014.
We summarised objective response rates with binomial responses and their corresponding 
two-sided exact 95% CI by the Clopper-Pearson method.18 We assessed duration of 
response, progression-free survival, and overall survival by the Kaplan-Meier product-limit 
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method. We also calculated median duration of response, progression-free survival, and 
overall survival with two-sided 95% CI by the per Brookmeyer and Crowley method.19 We 
used the Greenwood formula,20 to calculate overall survival and 95% CIs from the Kaplan-
Meier estimates. The primary safety analysis was based on adverse events reported within 
30 days of the last dose of nivolumab. We also assessed adverse events occurring within 100 
days of the last nivolumab dose for consistency with the primary analysis. We did the 
statistical analyses with SAS (version 9.02).
This study is registered with ClinicalTrials.gov, number NCT01721759.
Role of the funding source
The funder provided the study drug and worked with investigators to design the study, 
collect and analyse data, and interpret the results. All authors made the decision to submit 
the report for publication, and all drafts of the report were prepared by the corresponding 
author with input from coauthors and editorial assistance from a professional medical writer, 
funded by the sponsor. Raw data were reviewed and made accessible to the authors and 
professional medical writers.
Results
From Nov 16, 2012, to July 22, 2013, we enrolled 140 patients, of whom 117 (84%) were 
treated with nivolumab (appendix). 23 enrolled patients were not treated for the following 
reasons: no longer met study eligibility criteria (n=20), died before treatment (n=2), or lost 
to follow-up (n=1). Table 1 shows the patients’ characteristics. The patient population was 
highly refractory, with almost two-thirds having previously received three or more systemic 
treatments. Progressive disease was the most common best response to the most recent 
previous treatment, with more than three-quarters of patients entering the study within 3 
months of completing their most recent treatment (table 1). Half the patients had three or 
more baseline disease sites with at least one lesion (appendix). Four patients had brain 
metastasis at baseline. Median time from initial lung cancer diagnosis to nivolumab 
treatment was 1·7 years (IQR 1·1–2·6).
A median of six doses (IQR 3·0–14·0) of nivolumab were administered, with a median 
treatment duration of 2·3 months (95% CI 1·4–2·8). The minimum follow-up for IRC-
assessed response (calculated based on the date of last patient first visit to the date of last 
patient last visit) was 11·0 months, and the median follow-up for overall survival was 8·0 
months (IQR 3·7–12·0). Disease progression was the most common reason for 
discontinuation (78 [67%] of 117 patients; appendix).
After discontinuing nivolumab, 28 (24%) of 117 patients received subsequent systemic 
cancer treatment, most commonly gemcitabine (12 [10%]), docetaxel (five [4%]), and 
vinorelbine (five [4%]). No patients received subsequent immunotherapy.
17 (14·5%, 95% CI 8·7–22·2) of 117 patients achieved a partial response according to the 
independent radiology review committee. 30 (26%, 18–35) of 117 patients had stable 
disease, including one unconfirmed responder (a patient who had at least 30% reduction in 
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target lesion tumor burden, but without a subsequent scan confirming a response); 51 (44%, 
34–53) had progressive disease, seven (6%, 2–12) had indeterminate best overall response, 
and 12 (10%, 5–17) were not reported. Patients who were not evaluable for imaging plus 
clinical best overall response were listed as having indeterminate best overall response. 
Patients without on-study scans were listed as having unreported best overall response (six 
patients died before disease assessment, three had investigator-assessed progressive disease, 
and one patient each was unreported because of early discontinuation because of toxic 
effects, clinical progression without CT scan, and no subsequent scan taken after cycle 1, 
day 1).
Eight (47%) of 17 confirmed responders had progressive disease as the best overall response 
to their previous treatment, and had started nivolumab within 3 months of completing their 
most recent treatment (appendix). Target tumour lesion burden was reduced by at least 50% 
for 11 (65%) of 17 responding patients (figure 1). 29 (69%) of 42 patients with any reduced 
tumour burden, including all patients with a confirmed partial response, were alive at the 
time of this analysis (figure 1). Some patients without evidence of tumour regression were 
also alive at the time of analysis. Two patients with non-target baseline CNS metastases had 
responses in their CNS lesions, one with a systemic best overall response of stable disease, 
and another with a partial response. Nivolumab treatment led to objective responses 
independent of age, sex, baseline performance status, region, ethnic origin, and number of 
previous treatments, with numerical differences noted in some subgroups probably 
attributable to small sample sizes (appendix). Figure 2 shows changes of target tumour 
burden over time as assessed per the IRC.
Median time to response was 3·3 months (IQR 2·2–4·8). 13 (77%) of 17 responding patients 
had ongoing responses at the time of analysis (eight on-treatment, five in follow-up), and 
median duration of response had not been reached (95% CI 8·3 months to not reached). 30 
(26%) of 117 patients had stable disease as their best overall response, including one 
unconfirmed responder. Median duration of stable disease was 6·0 months (95% CI 4·7–
10·9), with 20 patients progression-free at the time of analysis.
By investigator assessment, one (1%) patient had a confirmed complete response, and 14 
(12%) had a confirmed partial response (12·8% [95% CI 7·4–20·3] achieved an objective 
response; appendix). The concordance rate between independent radiology review 
committee and investigator-assessed response was 92·2% based on the March 6, 2014, 
analysis. 22 (42%) of 52 patients continued nivolumab treatment after progression 
(appendix).
Median progression-free survival was 1·9 months (95% CI 1·8–3·2), with progression-free 
survival of 25·9% (18·0–34·6) at 6 months and 20·0% (12·7–28·5) at 1 year (figure 3A). 
Median overall survival was 8·2 months (95% CI 6·1–10·9) and overall survival at 1 year 
was 40·8% (31·6–49·7; figure 3B). At the time of analysis, 72 (62%) of 117 participants had 
died.
We obtained pretreatment archival tumour samples for 86 (74%) of 117 participants, 76 
(88%) of which could be assessed for PD-L1 expression. Median time from biopsy to start 
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of nivolumab treatment for all collected tumour samples was 1·3 years (IQR 0·8–2·1). 25 
(33%) of 76 patients had PD-L1-positive tumours (≥5% expression). Patients with PD-L1-
positive tumours and those with PD-L1-negative tumours achieved an objective response, 
with more objective responses in patients with PD-L1-positive tumours (table 2). Almost a 
third of patients with unevaluable PD-L1 expression had an objective response (table 2). The 
appendix shows objective response by PD-L1 status using other cutoff s. Reductions in 
target tumour lesion burden were more common in patients with PD-L1-positive tumours 
(13 [52%] of 25 patients) than in those with PD-L1-negative tumours (15 [38%] of 40; 
appendix).
32 (27%) of 117 patients had a dose delay, most often because of an adverse event, with 21 
(66%) of 32 having only one delay. Most dose delays lasted less than 15 days. Accordingly, 
99 (85%) of 117 patients received at least 90% of their planned dose intensity.
Almost three-quarters of patients reported a treatment-related adverse event of any grade; 
most commonly, fatigue, decreased appetite, and nausea (table 3). Grade 3–4 treatment-
related adverse events occurred in about a sixth of patients, most commonly fatigue, 
pneumonitis, and diarrhoea (table 3). Most treatment-related immune-mediated adverse 
events were of low grade, with skin disorders and gastrointestinal events most prevalent 
(appendix). Three patients had treatment-related grade 3 diarrhoea, which resolved with 
either corticosteroid treatment (one patient) or supportive care. Six patients had treatment-
related pneumonitis (none grade 4 or 5); one additional grade 3 pneumonitis was reported 
between 30 and 100 days after the last dose of nivolumab. All patients with pneumonitis 
were treated with corticosteroids, with a median time to resolution of 3·4 weeks (range 1·6–
13·4). Four low-grade, treatment-related, renal adverse events were reported, none of which 
were grade 3–4. Treatment-related adverse events led to discontinuation for 14 (12%) of 117 
patients: five (4%) for pneumonitis, two (2%) for fatigue, and one (1%) for each of 
anaphylactic reaction, hypersensitivity, adrenal insufficiency, diarrhoea, polyneuropathy, 
rash, and sensory neuropathy in both hands. At time of analysis, 15 (13%) of 117 patients 
were on treatment.
Two deaths were attributed, by the investigator, to nivolumab. One patient died of hypoxic 
pneumonia 28 days after the last dose of nivolumab. This patient had rapid tumour 
progression and bronchial obstruction with possible associated opportunistic infection. 
Although this condition was distinct from pneumonitis, the investigator reported the adverse 
event as possibly related to nivolumab as an inflammatory component could not be ruled 
out, and no bronchoscopy or autopsy was done. A second patient died of ischaemic stroke 
41 days after the first and only nivolumab dose. Both patients had multiple comorbidities 
and progressive disease (appendix).
Discussion
Our findings show that nivolumab monotherapy provides clinically meaningful activity and 
an acceptable safety profile for patients with advanced refractory squamous non-small-cell 
lung cancer. The prognosis for patients who have progressed after treatment with two or 
more chemotherapy regimens is very poor. No standard treatments exist for such patients, 
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other than best supportive care or experimental treatment in clinical trials, and new drugs are 
urgently needed.
To the best of our knowledge, CheckMate 063 is the first phase 2 study to report the activity 
of a PD-1 immune checkpoint inhibitor for advanced non-small-cell lung cancer (panel). 
Although systemic chemotherapy provides modest therapeutic gains for patients with 
advanced squamous non-small-cell lung cancer, patients progress after chemotherapy and 
have few treatment options beyond second-line treatment. Immunotherapy harnesses the 
ability of the immune system to recognise non-self tumour antigens, and to constantly adapt 
and detect new antigens, and thus holds promise as a novel therapeutic approach for several 
cancers including non-small-cell lung cancer.
The results of our study corroborate data from a phase 1 study.6,7 An IRC-assessed objective 
response in 14·5% of patients treated with nivolumab is a clinically meaningful 
improvement over previously reported objective response rates (2–8% of patients),12–14 
within the context of a single arm study; furthermore, responses were durable. Subgroup 
analyses showed objective responses within each subpopulation. Although a smaller 
proportion of women than men had an objective response, the small sample size and lack of 
published reports to address potential differences between sexes for this class of drugs for 
other tumour types precludes further conclusions.
Our patient population was refractory to treatment: most patients had received at least three 
previous regimens, had progressive disease as the best response to their most recent 
treatment, and entered the study within 3 months of completing their most recent treatment. 
Despite this fact, eight responses occurred in patients who had progressed on their most 
recent previous treatment therapy, and entered within 3 months of completing the most 
recent treatment, showing the activity of nivolumab for patients with aggressive disease. 
Although the time from initial diagnosis of advanced disease to nivolumab treatment was not 
recorded, it would be unusual for a patient with stage IV disease to have a substantial lag 
between diagnosis and treatment, and we do not expect it to substantially alter the results. 
Additional evidence of a therapeutic benefit was noted in the form of durable stable disease 
in many patients, clinical activity for CNS disease, and non-conventional responses in 
patients who continued nivolumab after disease progression, suggesting an immune-related 
pattern of antitumour activity.
1-year overall survival exceeded expectations based on previous reports for this population, 
although cross-trial comparisons should be made with caution in patients with squamous 
non-small-cell lung cancer.12–14 17% of participants had stage IIIB disease and the 
prognosis for such patients who have malignant effusion is much the same as for stage IV 
disease, making it unlikely that this subgroup accounts for the longer survival. Furthermore, 
because all patients entered this study with advanced, chemotherapy-refractory disease, there 
is no distinction between these subsets in terms of prognosis. Survival at 1 year and beyond 
is a useful measure of benefit of nivolumab and other immune-oncological treatments.21
Several studies have assessed PD-L1 expression as a potential biomarker of response to 
drugs targeting the PD-1 pathway,5,22–26 although the best cutoff is yet to be defined. Use of 
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a 10% cutoff for PD-L1 positivity resulted in the same classification of patients as with a 5% 
cutoff.
Some PD-L1 expression-negative patients had an objective response, suggesting that 
nivolumab has activity in this subgroup. Although objective responses were numerically 
higher in patients with positive PD-L1 expression, interpretation of these results is limited 
because of the small sample size and wide confidence intervals. Although the samples were 
archived and intervening treatment might have affected PD-L1 status at the time of 
nivolumab initiation, activity of PD-1 blockade for PD-L1-negative patients has also been 
reported from contemporary biopsies.27 Although overexpression of PD-L1 might serve as a 
hallmark of tumours that have successfully evaded an immune response (and therefore might 
be more susceptible to therapeutic intervention with an anti-PD-L1 antibody), nivolumab 
could alleviate inhibitory T-cell signalling independently of tumoral PD-L1 expression, for 
example by blocking interactions with other PD-1 ligands such as PD-L2. In view of similar 
observations of clinical activity of anti-PD-1/PD-L1 therapeutic antibodies in PD-L1 
negative patients,22,25,26 PD-L1 expression might not be necessary for achieving objective 
response with this class of agents, or the clinical effect of PD-L1 expression might be better 
represented by other endpoints, such as survival.
Panel: Research in context
Systematic review
We searched PubMed and congress abstracts from the yearly meetings in the past 5 years 
of the American Society of Clinical Oncology, European Cancer Congress, and World 
Conference on Lung Cancer for the terms “PD-1”, “PD-L1”, “nivolumab”, 
“pembrolizumab”, “lambrolizumab”, “MPDL3280A”, and “MEDI4736”. No language 
restriction was used. We identified several phase 1 trials showing that PD-1 and PD-L1 
inhibitors have antitumour activity in advanced non-small-cell lung cancer and other 
ongoing phase 2 trials assessing the activity of PD-1 and PD-L1 inhibitors. However, 
results of these phase 2 trials have not yet been reported. Data from a phase 1 study5 of 
heavily pretreated patients with advanced non-small-cell lung cancer showed clinical 
activity with nivolumab that was much the same for non-squamous and squamous 
subtypes.
Interpretation
Nivolumab showed activity in patients with advanced, refractory, squamous non-small-
cell lung cancer and was associated with a manageable safety profile, consistent with 
previous studies. Our results suggest that nivolumab may be a promising future treatment 
for patients with advanced, refractory squamous non-small-cell lung cancer, and should 
be explored in randomised, controlled, phase 3 trials.
The tumour microenvironment is highly complicated. Colocalisation of PD-L1 and tumour 
infiltrating lymphocytes is predictive of response,28 and additional studies of melanoma29 
have shown that pre-existing CD8 T cells located at the invasive tumour margin are 
associated with expression of the PD-1 immune inhibitory axis and might predict response 
to treatment. PD-L1 expression by other tumour-infiltrating immune cells seems to correlate 
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with response.30 Results from ongoing randomised studies will help to further define the 
predictive or prognostic relationship between PD-L1 expression and nivolumab activity.
The safety profile of nivolumab was consistent with the phase 1 trial. Treatment-related 
immune-mediated adverse events were generally infrequent and not severe, and could be 
managed with established guidelines. Pneumonitis is a clinically important treatment-related 
adverse event associated with treatment of non-small-cell lung cancer, including with 
nivolumab.31–34 In our study, nivolumab-related pneumonitis was as common as in the phase 
1 trial.6,7 By contrast with cytotoxic chemotherapy,35 haematological toxic effects were 
infrequently reported with nivolumab. Moreover, a third or fewer of patients in our study had 
low-grade treatment-related fatigue, decreased appetite, nausea, asthenia, rash, or diarrhoea.
Few treatment options exist for advanced, refractory squamous non-small-cell lung cancer, 
with no clear standard of care. Our study shows clinically meaningful activity and a 
manageable safety profile of nivolumab for this patient population and supports assessment 
of nivolumab in phase 3 studies of first-line and second-line treatment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Best reduction of tumour size
Data are based on the IRC assessment of survival status in July, 2014. Includes patients with 
complete target lesion data, a baseline assessment, and at least one on-treatment assessment 
before progression or start of subsequent treatment (n=95). The line at −30% indicates the 
threshold for objective response per RECIST v1.1.
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Figure 2. Changes of target tumour burden over time as assessed per IRC
Shows changes by RECIST response (A), in patients with an objective response (B), in 
patients with stable disease (C), and in patients with progressive disease or for whom 
response could not be determined (D). Includes patients with an evaluable response (n=100), 
who had a baseline assessment and at least one on-treatment tumour assessment. Tumour 
burden was measured as the sum of the longest diameters of target lesions. 
RECIST=Response Evaluation Criteria In Solid Tumors. SD=stable disease. PR=partial 
response. PD=progressive disease.
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Figure 3. Kaplan-Meier analysis of progression-free survival (A) and overall survival (B)
Progression-free survival was IRC assessed.
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 Median (IQR) 65 (57–71)
 <75 101 (86%)
 ≥75 16 (14%)
Sex
 Male 85 (73%)
 Female 32 (27%)
Ethnic origin
 White 99 (85%)
 Black or African American 11 (9%)
 Asian 2 (2%)
 Other 5 (4%)
ECOG PS
 0 26 (22%)
 1 91 (78%)
Disease stage
 IIIB 20 (17%)
 IV 97 (83%)
History of smoking 108 (92%)
CNS metastasis 2 (2%)*
Previous systemic therapy
 Platinum-based therapy 117 (100%)
 Other 117 (100%)
 EGFR TKI 39 (33%)
 Experimental treatment 13 (11%)
Number of previous systemic treatments
 2 41 (35%)
 3 52 (44%)
 ≥4 24 (21%)
Previous radiotherapy 87 (74%)
Best response to most recent previous treatment
 CR or PR 5 (4%)
 SD 32 (27%)
 Progressive disease 71 (61%)
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Patients (n=117)
 Unknown 9 (8%)
Months from completion of most recent previous regimen to treatment in this study
 <3 89 (76%)
 3–6 16 (14%)
 >6 12 (10%)
Data are n (%) unless otherwise stated. CR=complete response. ECOG PS=Eastern Cooperative Oncology Group performance status. TKI=tyrosine 
kinase inhibitor. CR=complete response. PR=partial response. SD=stable disease.
*
Two additional patients had CNS metastasis at baseline but were not included here because the characteristic was reported after the date of data 
analysis. Of the four patients with brain metastasis, two had received radiation treatment: one required on-study brain radiotherapy at day 35, 
because of increasing headache, and one had previous stereotactic radiosurgery.
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Table 2
Best overall response by PD-L1 expression status
Partial response Stable disease Progressive disease
<5% (n=51) 7 (14%) 10 (20%) 25 (49%)
≥5% (n=25) 6 (24%) 6 (24%) 11 (44%)
Unevaluable (n=10) 3 (30%) 4 (40%) 2 (20%)
Data are n (%). Patients with indeterminate best overall response (n=7), and best overall response not reported by the IRC (n=5) are not included. 
PD-L1 expression was evaluable in all these patients, except one with best overall response not reported.
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Table 3
Treatment-related adverse events that occurred in at least 5% of all treated patients
Any grade Grade 3–4
Any 87 (74%) 20 (17%)
General disorders
 Fatigue 38 (33%) 5 (4%)*
 Asthenia 14 (12%) 0
Gastrointestinal disorders
 Nausea 18 (15%) 0
 Diarrhoea 12 (10%) 3 (3%)*
 Dry mouth 7 (6%) 0
 Vomiting 7 (6%) 0
 Constipation 6 (5%) 0
Metabolism and nutrition disorders
 Decreased appetite 22 (19%) 0
Skin and subcutaneous tissue disorders
 Rash 13 (11%) 1 (1%)*
 Pruritus 7 (6%) 1 (1%)*
Musculoskeletal disorders
 Myalgia 6 (5%) 1 (1%)*
Respiratory disorders
 Dyspnoea 6 (5%) 0
 Pneumonitis 6 (5%) 4 (3%)*
Blood and lymphatic system disorders
 Anaemia 7 (6%) 1 (1%)*
Data are number of events (%). Includes events reported between the first dose and 30 days after the last dose of nivolumab. Grade 3–4 adverse 
events reported by less than 5% of patients included: hyponatraemia (two [2%]); and polyneuropathy, decreased lymphocyte count, herpes zoster, 
adrenal insufficiency, vasculitis, hypersensitivity, anaphylactic reaction, and unassigned, each reported by one patient (one [1%]). One patient (1%) 
died from pneumonia, and one patient (1%) from ischaemic stroke.
*
All grade 3.
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